AAM
IOVA icon

Advisors Asset Management’s Iovance Biotherapeutics IOVA Stock Holding History

Advisors Asset Management’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-3,941
Closed -$24.1K – 1440
2023
Q1 		$24.1K Sell
3,941
-201
-5% -$1.39K ﹤0.01% 1372
2022
Q4 		$26.5K Sell
4,142
-39,026
-90% -$305K ﹤0.01% 1412
2022
Q3 		$414K Sell
43,168
-4,271
-9% -$49.3K 0.01% 971
2022
Q2 		$524K Sell
47,439
-9,883
-17% -$130K 0.01% 930
2022
Q1 		$954K Sell
57,322
-35,845
-38% -$554K 0.01% 824
2021
Q4 		$1.78M Sell
93,167
-1,611
-2% -$35.5K 0.03% 646
2021
Q3 		$2.34M Buy
94,778
+1,387
+1% +$32.7K 0.04% 549
2021
Q2 		$2.43M Buy
93,391
+16,432
+21% +$427K 0.03% 542
2021
Q1 		$2.44M Buy
76,959
+35,396
+85% +$1.47M 0.04% 521
2020
Q4 		$1.93M Buy
41,563
+36,130
+665% +$1.43M 0.03% 568
2020
Q3 		$179K Buy
5,433
+2,517
+86% +$77.2K ﹤0.01% 1201
2020
Q2 		$80K Buy
+2,916
New +$95.9K ﹤0.01% 1341

Other funds holding IOVA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

Advisors Asset Management's IOVA Position: Q2 2023 in Review

Advisors Asset Management sold out of Iovance Biotherapeutics (IOVA) in Q2 2023, closing a stake of 3,941 shares — an estimated $24.1K sold.

Advisors Asset Management first reported a position in IOVA in Q2 2020 and held it in 12 quarters. The position peaked at $2.44M in Q1 2021. 219 funds tracked by Wall St. Rank hold IOVA as of Q2 2023.

  • Advisors Asset Management reported no remaining Iovance Biotherapeutics position as of Q2 2023 after selling out during the quarter.
  • Advisors Asset Management sold 3,941 Iovance Biotherapeutics shares in Q2 2023, an estimated $24.1K.
  • Advisors Asset Management first reported a position in Iovance Biotherapeutics in Q2 2020 and held it in 12 quarters.
  • Advisors Asset Management's Iovance Biotherapeutics position peaked at $2.44M in Q1 2021.
  • 219 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2023.

Based on Advisors Asset Management's 13F filing for Q2 2023, filed 14 Aug 2023.